Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals has entered an agreement to acquire Increlex, a biologic product for treating severe primary insulin-like growth factor 1 deficiency, from Ipsen. The terms of the deal were not disclosed. Increlex is approved in 40 territories, including the U.S. and EU, and is the only FDA and EMA approved treatment for SPIGFD.
October 03, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eton Pharmaceuticals is acquiring Increlex from Ipsen, potentially expanding its product portfolio with a unique FDA-approved treatment for SPIGFD.
The acquisition of Increlex could significantly enhance Eton's product offerings, as it is the only FDA-approved treatment for SPIGFD. This could lead to increased revenue and market presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Ipsen is selling Increlex to Eton Pharmaceuticals, which may impact its revenue stream from this product.
Ipsen's sale of Increlex could reduce its revenue from this product, which had global sales of €17.3 million in 2023. This may impact Ipsen's financials negatively in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70